BOCA RATON, Fla., June 13, 2016 /PRNewswire/ -- Sensus Healthcare,
Inc. (NASDAQ: SRTSU), a medical device company specializing in the
treatment of non-melanoma skin cancers and other skin conditions,
such as keloids, with superficial radiation therapy, today
announced the appointment of Darrell S.
Rigel, MD, MS, to its Board of Directors. Dr. Rigel is
a Clinical Professor of Dermatology at New
York University Medical Center and serves as Medical
Director of the Schweiger Dermatology Group. He has also served as
President of the American Academy of Dermatology and as a Director
of the American Board of Dermatology. In addition, he is a
past President of both the American Society for Dermatologic
Surgery and American Dermatological Association.
Dr. Rigel stated, "I am honored to join the Board of Directors
of Sensus Healthcare. Having dedicated my professional life to
dermatology, I have seen the impact that skin disorders have on my
patients on a daily basis. With its innovative technology and
non-invasive approach to treating skin cancer and keloids, Sensus
Healthcare has taken a leadership position in treating skin cancer
in a cost-effective manner and addressing the medical needs of
large, underserved populations. I am confident that Sensus
Healthcare will have an increasingly significant impact on patient
care and I look forward to helping the Company expand access to
their technologies for physicians and patients."
Joe Sardano, Chief Executive
Officer for Sensus Healthcare, added, "I am gratified Dr. Rigel has
chosen to apply his experience and passion to the advancement of
Sensus. Dr. Rigel joining the board speaks volumes about our value
in the dermatology and skin cancer markets and shows how we are
truly making a difference in the lives of our patients. In Dr.
Rigel, we have secured the ideal board member: a highly recognized
leader in the field of dermatology who brings to bear tremendous
public and private company experience. I am confident he will be an
enormous asset to Sensus for years to come."
Dr. Rigel is a well-respected leader in dermatology and has
chaired numerous national and international conferences and
symposiums, delivering more than 900 presentations. He has authored
many articles and abstracts in professional journals and is the
lead editor of Cancer of the Skin, the primary textbook in
the field. Dr. Rigel has testified before Congress and the
FDA on dermatology-related issues and frequently serves as an
expert on national television and in magazines and newspapers that
include CNN, ABC, FOX, NBC, CBS, The New York Times and Wall Street
Journal.
Currently, Dr. Rigel is a member of the Board of Directors for
Foamix Pharmaceuticals and Chief Medial Advisor to the Board of
Directors of Strata Skin Sciences. He has also served as a board
member for Lumenis and Triax Pharmaceuticals.
Dr. Rigel graduated from MIT with a
BS in Management Information Science, has an MS (MBA) from the
Sloan School of Management at MIT and
received his MD from George Washington
University. He attended Cornell
University Medical Center for an internship in Internal
Medicine and completed his training at New
York University where he was Resident, Chief Resident, NIH
Training Fellow and Dermatology Surgery Fellow.
Dr. Rigel has been widely recognized for his achievements in the
field of dermatology:
- American Academy of Dermatology's Gold Medal – the highest
award in the specialty in recognition of a lifetime of
achievement
- George B. Morgan Award from
MIT recognizing exceptional achievement
by an alumnus
- Humanitarian Award of the Melanoma Research Foundation
- American Cancer Society's National Honor Citation for Skin
Cancer Programs
- Presidential Citations from the Academy and American Society
for Dermatologic Surgery for public education programs in skin
cancer
About Sensus
Sensus Healthcare, Inc. is a medical
device company that is committed to enabling non-invasive and
cost-effective treatment of non-melanoma skin cancers and keloids.
Sensus uses a proprietary low energy x-ray radiation technology
known as superficial radiation therapy (SRT), which is a result of
over a decade of dedicated research and development activities.
Sensus has successfully incorporated the SRT therapy into its
portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™.
To date, the SRT technology has been used to effectively and safely
treat oncological and non-oncological skin conditions in thousands
of patients. For more information, visit
http://www.sensushealthcare.com.
Investor Relations:
Jeffrey
Goldberger / Allison Soss
KCSA Strategic Communications
Phone: 212-896-1249 / 212-896-1267
Email: jgoldberger@kcsa.com / asoss@kcsa.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/sensus-healthcare-inc-appoints-dr-darrell-rigel-to-its-board-of-directors-300283455.html
SOURCE Sensus Healthcare